ArticleAnnals of neurology2008
Future of cell and gene therapies for Parkinson's disease.
Article in Annals of neurology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 52 citations in OpenAlex.
- Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients.Frontiers in cellular neuroscience · 2020Review
- Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.Nano letters · 2017Article
- Transplantation of Airway Epithelial Stem/Progenitor Cells: A Future for Cell-Based Therapy.American journal of respiratory cell and molecular biology · 2017Article
- Molecular heterogeneity of midbrain dopaminergic neurons--Moving toward single cell resolution.FEBS letters · 2015Review
- Neuromechanical principles underlying movement modularity and their implications for rehabilitation.Neuron · 2015Review
- Pluripotent stem cells for Parkinson's disease: progress and challenges.Stem cell research & therapy · 2013Review
- Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function.Gene therapy · 2012Review
- Stem cell challenges in the treatment of neurodegenerative disease.CNS neuroscience & therapeutics · 2012Review
- Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Review
- Progress and prospects: stem cells and neurological diseases.Gene therapy · 2011Review
- Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Review
- Recent advances in lentiviral vector development and applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- A dual-hit animal model for age-related parkinsonism.Progress in neurobiology · 2010Review
- Spatiotemporally separable Shh domains in the midbrain define distinct dopaminergic progenitor pools.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.Neurobiology of disease · 2009Article
- Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients.Journal of neurology · 2009Review
- Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The experimental field of restorative neurology continues to advance with implantation of cells or transfer of genes to treat patients with neurological disease. Both strategies have generated a consensus that demonstrates their capacity for structural and molecular brain modification in the adult brain. However, both approaches have yet to successfully address the complexities to make such novel therapeutic modalities work in the clinic. Prior experimental cell transplantation to patients with PD utilized dissected pieces of fetal midbrain tissue, containing mixtures of cells and neuronal types, as donor cells. Stem cell and progenitor cell biology provide new opportunities for selection and development of large batches of specific therapeutic cells. This may allow for cell composition analysis and dosing to optimize the benefit to an individual patient. The biotechnology used for cell and gene therapy for treatment of neurological disease may eventually be as advanced as today's pharmaceutical drug-related design processes. Current gene therapy phase 1 safety trials for PD include the delivery of a growth factor (neurturin via the glial cell line-derived neurotrophic factor receptor) and a transmitter enzyme (glutamic acid decarboxylase and aromatic acid decarboxylase). Many new insights from cell biological and molecular studies provide opportunities to selectively express or suppress factors relevant to neuroprotection and improved function of neurons involved in PD. Future gene and cell therapies are likely to coexist with classic pharmacological therapies because their use can be tailored to individual patients' underlying disease process and need for neuroprotective or restorative interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.